Diabetes

This activity is supported by an independent educational grant from Abbott Diabetes Care.

Both semaglutide and dulaglutide are dosed once weekly for treatment of type 2 diabetes.

The FDA has approved triple-combination extended release tablets to lower blood sugar in adults with type 2 diabetes (T2D), when combined with diet and exercise.

A recent study shows that diabetes risk is associated with younger age at onset of obesity, and longer exposure to obesity.

Lower-priced versions of Humalog Mix75/25 KwikPen and Humalog Junior KwikPen will be available in mid-April and will have 50% lower list prices compared with branded versions.

The treatment is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation, according to Novo Nordisk.

The immunogenicity and safety of hepatitis B surface antigen (HBsAg)/CpG 1018 was assessed in patients with diabetes aged 60 to 70 years.

Results of the DAPA-HF trial demonstrate the efficacy and safety of dapagliflozin in patients with heart failure.

Rates of some vaccinations are low in these patients, but pharmacists can play a key role in adherence.

According to Janet Woodcock, MD and director of FDA’s Center for Drug Evaluation and Research, the agency is focused on the drugs used by Americans continuing to meet “strict quality standards.”

A new study has found that patients with heart failure with reduced ejection fraction receiving dapagliflozin decreased their risk of worsening HF or death from cardiovascular events.

The approval was based on a phase 3 EDITION JUNIOR trial evaluating children and adolescents, aged 6 to 17 years, living with type 1 diabetes.

Ocular conditions can lead to serious complications, and sometimes there are no early symptoms.

Metformin hydrochloride extended-release tablets are indicated to for improving glycemic control in patients with type 2 diabetes mellitus, as an adjunct to diet and exercise.

Clinical data has illustrated how digital interventions can have a substantial material benefit on glycemic control in users with diabetes, with 73 of 162 users in the study reducing their average blood glucose levels to under 140 mg/dL.

In honor of World Diabetes Day, AstraZeneca has launched the campaign Diabetes Can Break Your Heart, the national movement aimed to change the trajectory of heart failure in type 2 diabetes.

Top news of the day from across the health care landscape.

What is causing this patient to lose her sense of smell?

Pharmacists can help with product selection and counsel on routine self-monitoring.

Confirming latent autoimmune diabetes in adults and dispensing the correct tube size for triaminoclone.

This intervention fosters connections with patients, identifies treatment goals, and increases adherence.

Top news of the day from across the health care landscape.

Officials from the FDA have expanded the label of insulin aspart injection pumps, 100 u/mL (Fiasp, Novo Nordisk) to include use in insulin infusion pumps.

Treatment depends on the patient, but adherence to the ever-changing guidelines is key.

A study has found that young adults with diabetes have high rates of cardiometabolic risk factors such as adiposity, blood pressure, chronic kidney disease, and history of cardiovascular disease. These risk factors can lead to an increased disease prevalence and mortality rate among these young adults as they age.

The study aimed to determine the association between antidepressant classes, types, and duration of use during pregnancy and the risk of gestational diabetes.

Officials from the FDA have approved the Janssen Pharmaceutical Companies of Johnson & Johnson’s canagliflozin (Invokana) to reduce the risk of end-stage kidney disease (ESKD) and cardiovascular events in patients with Type 2 Diabetes and chronic kidney disease (CKD).

The FDA has granted approval of Rybelsus (semaglutide) oral tablets 7 mg or 14 mg to Novo Nordisk. The drug is the first oral glucagon-like peptide (GLP-1) receptor protein treatment for type 2 diabetes.

A recent clinical study demonstrated positive long-term benefits of the early intervention combination treatment of metformin plus vildagliptin (Galvus, Norvartis), a dipeptidyl peptidase-4 [DPP-4] inhibitor, for type 2 diabetes (T2D).

The glucagon injection is designed to reduce the steps and time needed to prepare and administer medicine for severe hypoglycemia.